Discussion  by unknown
values, because our experience has not found that strategy to
be advantageous.23 It is possible that subgroups among the
patients with negative mediastinal PET scans could be iden-
tified for whom the risk of mediastinal metastases is low
enough to justify avoiding mediastinoscopy. A cost analy-
sis, including the costs and risks of mediastinoscopy, would
be required to answer this question.
PET represents an important advance in the staging of
lung cancer. The use of PET in staging the mediastinum
must take into account the significance of false-positive and
false-negative results. A positive PET scan result does not
necessarily represent malignant disease, and histologic con-
firmation is always warranted. In this setting, PET may be
useful to direct biopsies, especially if initial biopsy results
are unexpectedly negative.10 A negative PET scan result is
relatively powerful (negative predictive value 88.3%). Nev-
ertheless, mediastinoscopy may identify N2 or N3 disease in
this group of patients. Mediastinoscopy remains the crite-
rion standard in staging the mediastinum in patients with
lung cancer.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). I congratulate Gonzalez-
Stawinski and colleagues at Duke for an important contribution
that refines our knowledge of the role of PET scanning in lung
cancer staging. The recent enthusiasm with PET imaging mirrors
almost exactly the experience that we had with the introduction of
CT scanning in the 1970s. Initial reports suggested that CT had
sensitivity and specificity for mediastinal lymph node involvement
greater than 90% and that mediastinoscopy was no longer neces-
sary. Paradoxically, as experience and technology improved, the
reports of accuracy diminished, and nearly all experienced thoracic
surgeons still considered mediastinoscopy was necessary to con-
firm positive mediastinal lymph nodes. Many of us have felt that
the poor sensitivity of CT supports the use of routine mediastinos-
copy to better direct patients into multimodality protocols and to
avoid the morbidity of nontherapeutic thoracotomies.
The initial experience and data with PET again suggested that
mediastinoscopy is no longer necessary for lung cancer staging.
Most of the early PET articles reported accuracy greater than 90%,
but Gonzalez-Stawinski and colleagues have shown us more ma-
ture results with careful pathologic correlation. In our own expe-
rience reported last year, PET correctly differentiated N0-1 disease
from N2-3 disease in 91% of patients, with both positive and
negative predictive values of 90%. Although this is better than
found in this series, it led us to the same conclusion, that there are
high enough incidences of both false-positive and false-negative
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results to support routine mediastinal evaluation by mediastinos-
copy.
Dr Gonzalez-Stawinski, I have three questions related to your
experience. First, although you performed PET in almost 2000
patients with lung cancer, only 202, or about 10%, had mediasti-
noscopy after PET. What selection factors excluded the other 90%
of patients, and how might this have skewed your results?
Second, you had a surprising incidence of false-positive PET
studies, higher than most other reports. Do you think that this is
due to setting a low threshold for mediastinal nodal positivity? Do
you now use a more quantitative standard uptake value (SUV)
threshold to evaluate lymph nodes?
Finally, even T1 tumors with a normal appearing mediastinum
have a 10% to 15% incidence of N2 nodal disease. Given your
experience showing a low sensitivity for positive mediastinal
lymph nodes, have you moved to a strategy of routine mediasti-
noscopy? I applaud your fine work and your elegant presentation,
and I thank you for helping us clarify the value of PET in lung
cancer staging.
Dr Gonzalez-Stawinski. Thank you for your kind comments.
Let me address the first question in regard to the patients that we
excluded. It is true that we excluded 1756 patients. The reason
behind that is that we are a center that essentially offers PET scan
to an entire region, and a lot of these patients underwent PET scan
in our institution without any follow-up or having any therapy
afterward. In addition, a large number of patients had stage IV
disease, at least as detected by PET scan.
In reference to the use of SUVs, essentially our decision to not
use SUVs is based on reports from our own institution published
in 1994 in the Journal of Nuclear Medicine by Lowe and cowork-
ers showing that in our hands visual analysis of PET was superior
to semiquantitative analysis with SUVs.
Finally, in reference to in which cases we are doing mediasti-
noscopy, we choose those patients that have T2 or T3 tumors,
patients with enlarged lymph nodes, patients who are on protocol
studies, and patients who are at high medical risk.
Dr Larry R. Kaiser (Philadelphia, Pa). I enjoyed the article,
and it certainly supports some of our own views. You mentioned
the size of the lymph nodes. Ned Patz at your institution, who has
been one of the leading proponents of PET, has basically stated
that PET shouldn’t exist in a vacuum, and the combination of the
CT scan and PET probably is a better predictor. Have you looked
at the size of the lymph nodes? I know you did mediastinoscopy if
the nodes were greater than 1 cm, but has there been a better
predictive value with PET with the larger nodes?
Also, what has the experience been in your institution with
using PET for solitary pulmonary nodules? Are you still optimistic
about that? Our own experience has led us to become less enthu-
siastic, in fact, with solitary nodules.
Dr Gonzalez-Stawinski. Thank you for your questions. With
regard to the size of the lymph nodes, in this particular study we
did not analyze the size with respect to outcome. And I agree with
you regarding the utility of PET for pulmonary nodules; in our
own experience, we are less optimistic about the results of PET
scan for solitary pulmonary nodules.
Dr Hiran C. Fernando (Pittsburgh, Pa). I congratulate you on
your presentation. Two quick questions. In your false-positive
cases, what was the incidence of granulomatous inflammation, and
in the false-negative cases, what was the incidence of bronchiolar
carcinoma?
Dr Gonzalez-Stawinski. Thank you for your question. When
we broke down the cases that had benign lesions, we saw 6 patients
who had essentially obstructive pneumonia, 5 patients with gran-
ulomatous disease, and 1 patient with silicosis.
Gonzalez-Stawinski et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 1905
G
TS
